What Are Medicinal Properties?
Biomedicine refers to the use of research results in biology, medicine, biochemistry, etc., and the comprehensive use of the principles and methods of physics, chemistry, biochemistry, biotechnology, and pharmaceutics. A class of products used for prevention, treatment and diagnosis. Biopharmaceuticals, including biotechnology drugs and probiotics.
Biomedicine
- Biomedicine refers to the application of research results in biology, medicine, biochemistry, etc., and the comprehensive use of the principles and methods of physics, chemistry, biochemistry, biotechnology, and pharmacy.
- Refers to the primary and secondary metabolites of an organism, including a biological product, or a component of an organism, and even the entire organism is used as a diagnostic and therapeutic drug.
- The reason why a normal body can maintain a healthy state and have the ability to resist and self-defeated diseases is precisely because various kinds of regulatory substances closely related to the metabolism of the organism, such as proteins, enzymes, nucleic acids, hormones, antibodies,
Asset size of biopharmaceutical industry
- According to the latest information, in the fourth quarter of 2012, the growth rate of assets in the biopharmaceutical manufacturing industry reversed the downward trend since the second half of 2011. At the end of 2012, the total assets of China's biopharmaceutical manufacturing industry reached 184.087 billion yuan, a year-on-year increase of 14.9%, a growth rate of 3.97 percentage points lower than the same period of the previous year, and an increase of 1.17 percentage points from the first three quarters [1] .
- Chart China's total assets and growth rate of biopharmaceutical manufacturing since 2009
- Total assets of biopharmaceutical manufacturing industry and year-on-year growth rate
- Due to the late start of China's biopharmaceutical industry, the upstream technology is 5 years behind compared to foreign countries, but the downstream technology is at least 15 years behind. The products are mostly concentrated in the lower-end generic vaccine and blood products industries. The technical barriers are low and the industry is still low. Mainly small and medium enterprises, the proportion of large enterprises is relatively low. At the end of 2012, in China's biopharmaceutical manufacturing industry, the proportion of assets of small enterprises increased to 38.02%, an increase of 1.12 percentage points from the first three quarters, and the proportion of assets of large enterprises fell to 17.17%, a decrease of 0.72 percentage points from the first three quarters.
- Chart China's Biopharmaceutical Manufacturing Assets Distribution by Enterprise Size Since 2010
- Distribution of China's Biopharmaceutical Manufacturing Assets by Enterprise Size
Current status of biopharmaceutical supply
- In 2012, the overall issuance of vaccines and other biological products showed an upward trend, and the batch of issuance of vaccine companies is gradually recovering. According to statistics from the China Food and Drug Testing Institute, in 2012, the number of batches of vaccines such as hepatitis A and B combined vaccines, pneumonia vaccines, rabies vaccines, haemophilus influenza b combined vaccines, and leprosy vaccines increased by more than 20 %, A year-on-year increase of 136.41%, 42.30%, 39.76%, 34.83%, and 26.51%, as MMR (measling gall vaccine) completely replaces measles, leprosy, and gills are the future development trend of the vaccine market, mumps, measles vaccine The number of batches issued such as rubella vaccine continued to decline, and the number of batches issued decreased by 43.48%, 47.03%, and 6.37% year-on-year.
- Table 2012 China's Major Vaccine Approval Issuance and Year-on-year Growth Rate Unit: 10,000 copies,%